• A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease 

      Wightman, Douglas P.; Jansen, Iris E.; Savage, Jeanne E.; Shadrin, Alexey; Bahrami, Shahram; Holland, Dominic; Rongve, Arvid; Børte, Sigrid; Winsvold, Bendik K S; Drange, Ole Kristian; Martinsen, Amy E.; Skogholt, Anne Heidi; Willer, Cristen; Bråthen, Geir; Bosnes, Ingunn; Nielsen, Jonas Bille; Fritsche, Lars; Thomas, Laurent; Pedersen, Linda Margareth; Gabrielsen, Maiken Elvestad; Johnsen, Marianne Bakke; Meisingset, Tore Wergeland; Zhou, Wei; Proitsi, Petroula; Hodges, Angela; Dobson, Richard; Velayudhan, Latha; Sealock, Julia; Davis, Lea K.; Pedersen, Nancy L.; Reynolds, Chandra A.; Karlsson, Ida K.; Magnusson, Sigurdur; Stefansson, Hreinn; Thordardottir, Steinunn; Jónsson, Pálmi V.; Snædal, Jon; Zettergren, Anna; Skoog, Ingmar; Kern, Silke; Waern, Margda; Zetterberg, Henrik; Blennow, Kaj; Stordal, Eystein; Hveem, Kristian; Zwart, John Anker Henrik; Athanasiu, Lavinia; Selnes, Per; Saltvedt, Ingvild; Sando, Sigrid Botne; Ulstein, Ingun; Djurovic, Srdjan; Fladby, Tormod; Aarsland, Dag; Selbæk, Geir; Ripke, Stephan; Stefánsson, Kári; Andreassen, Ole; Posthuma, Danielle (Journal article; Peer reviewed, 2021)
      Late-onset Alzheimer’s disease is a prevalent age-related polygenic disease that accounts for 50–70% of dementia cases. Currently, only a fraction of the genetic variants underlying Alzheimer’s disease have been identified. ...
    • Variation in serum PCSK9 (proprotein convertase subtilisin/kexin type 9), cardiovascular disease risk, and an investigation of potential unanticipated effects of PCSK9 inhibition 

      Brumpton, Ben Michael; Fritsche, Lars; Zheng, Jie; Nielsen, Jonas Bille; Mannila, Maria Nastase; Surakka, Ida; Rasheed, Humaira; Vie, Gunnhild Åberge; Graham, Sarah E.; Gabrielsen, Maiken Elvestad; Laugsand, Lars Erik; Aukrust, Pål; Vatten, Lars Johan; Damås, Jan Kristian; Ueland, Thor; Janszky, Imre; Zwart, John-Anker; van't Hooft, Ferdinand M.; Seidah, Nabil Georges; Hveem, Kristian; Willer, Cristen; Smith, George Davey; Åsvold, Bjørn Olav (Peer reviewed; Journal article, 2019)
      PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver. Although some long-term trials have evaluated their safety, ...